GSK-4381562

N/A

Report date: 2025/02/27 11:35:38

Base Information

Drug NameGSK-4381562
Drug Alias NameSRF-813GSK-4381562GSK-4381562AGSK4381562AGSK’562
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody
Mechanisms of ActionNatural killer cells stimulantsAntibody-dependent cell-mediated cytotoxicity (ADCC) effectsTransmembrane protein PVRIG antagonists +[4] 
TargetsTransmembrane protein PVRIG
Therapy Area/IndicationsSolid tumoursNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesAustralia +[9] 
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesSurface Oncology Inc
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesGlaxosmithkline PlcGlaxosmithkline (China) Investment Co Ltd
Inactive CompaniesSurface Oncology Inc
Active IndicationsSolid tumoursNeoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A